ArticleInternational journal of cardiology. Cardiovascular risk and prevention2026
Global burden of non-rheumatic calcific aortic valve disease in adults aged 60 years and older, with projections to 2041: insights from the Global Burden of Disease Study 2021.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to explore the most recent trends in NRCAVD burden among adults aged 60 years and older and to further predict trends up to 2041. Methods: We estimated the age-standardized incidence (ASIR), prevalence (ASPR), disability-adjusted life years (DALYs) (ASDALYsR) and death rates (ASDR) of NRCAVD in adults aged ≥60 years from 1990 to 2021 using data from the 2021 Global Burden of Disease Study. Temporal trends were quantified using average annual percent change and projections to 2041 were made using the Nordpred model. Results: Globally, in 2021, NRCAVD affected 11.78 million older adults (ASPR: 1122.7/100,000), with 0.84 million new cases (ASIR: 77.3/100,000), resulting in 132,764 deaths (ASDR: 13.7/100,000) and an ASDALYsR of 182 per 100,000. From 1990 to 2021, global ASIR and ASPR increased significantly (22.1 % and 24.8 %, respectively), while ASDALYsR and ASDR declined. High-income regions exhibited the greatest disease burden, notably High-income North America and Western Europe. Marked sex-based differences existed, with males showing higher burden compared to females. Projections indicate that by 2041, the absolute number of cases will rise by 72.1 %. Conclusions: The global burden of NRCAVD in older adults is substantial and varies by age, gender, socio-demographic index, and region. Despite declining age-standardized rates, the absolute burden of NRCAVD will increase, highlighting the need for early screening and improved treatment access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.